Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 6, 2018

View Archived Issues

IL-6-induced CD44 and PD-L1 expression confers cancer stem cell properties on bladder cancer cells

JAVELIN: Strong data will drive practice in first-line renal cell carcinoma

GPR40 activation alleviates epileptic seizures in animal models

T-type calcium channel antagonists protect dopaminergic neurons from apoptosis in Parkinson's

P2X7 receptor contributes to the hyperinflammatory response of localized aggressive periodontitis

Phase I data presented for BVAC-C in HPV16- or HPV18-positive recurrent cervical carcinoma

Preliminary results presented from TRITON2 study of rucaparib

New fully human skin cell culture facilitates grafting

TDP-43 aggregates at first do no harm

Lenvatinib demonstrates highest overall response rate with a targeted agent in neuroendocrine tumors

AK-111 begins first-in-human study in healthy subjects

Denali and Sanofi collaborate to develop RIPK1 inhibitors

ConSOSL.UFO replicon saRNA demonstrates high immunogenicity in vivo

REWIND study of Trulicity meets primary efficacy objective

Phase II study of GKT-831 in PBC meets primary and secondary interim efficacy endpoints

Promising interim results presented from phase I DRIIV-1 study of AsiDNA

PK and PD analysis in rhesus macaques of intravaginal ring containing the antiretroviral MK-2048

Administration of TDP-43 inhibitor PM-1 stops progression of AD in 5XFAD mice

Goldfinch Bio compound targets TRPC5 for the treatment of focal segmental glomerulosclerosis

VX-659/tezacaftor/ivacaftor triple combination regimen shows safety and efficacy in phase II study

Magenta Therapeutics patents AhR antagonists

DKFZ and TUM present EPHA2 inhibitors

International Stem Cell reports interim data from phase I study of ISC-hpNSC in Parkinson's

Clearside Biomedical discontinues Xipere combination therapy for RVO based on SAPPHIRE data

Eli Lilly identifies new EIF2AK3 inhibitors

Eli Lilly and NextCure enter immuno-oncology discovery and development collaboration

Bio-Thera Solutions initiates phase III trial of BAT-8001 in HER2-positive metastatic breast cancer

Novintum Biotechnology divulges azithromycin derivatives for cancer

Guangzhou Wellhealth Bio-Pharmaceutical discloses PARP-1 inhibitors

Phase III TIVO-3 trial of tivozanib in renal cell carcinoma meets primary endpoint

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...